Pilatus Biosciences pioneers innovative therapies using first-in-class antibodies and bifunctional proteins to target metabolic checkpoints, reprogramming the immune microenvironment to address cancer and immune-related diseases.
LEARN moreFirst-in-class, anti-CD36 monoclonal antibody; metabolic checkpoint inhibitor targeting lipid-mediated immunosuppression
More Information
Granted by the FDA to facilitate development and expedite review of PLT012 for hepatocellular carcinoma, a serious condition with high unmet medical need.

Granted by the FDA to support the development of PLT012 for hepatocellular carcinoma and intrahepatic bile duct cancer, including regulatory incentives and potential market exclusivity.
.png)
Raven Lin | Co-Founder and Chief Executive Officer of Pilatus Biosciences
Our mission is to create innovative immunotherapies that unlock the immune system's potential and improve lives by turning once-untreatable diseases into manageable conditions.





We are currently seeking strategic partners and investors to accelerate the development and commercialization of our lead candidate, PLT012, and expand our pioneering pipeline.
If you are exploring high-potential investment opportunities in biotech front or looking to collaborate on cutting-edge medical science, Pilatus invites you to connect with us!